Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 7714  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (637 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Introduction
 » Subjects and Methods
 » Results
 » Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed1749    
    Printed49    
    Emailed2    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2015  |  Volume : 63  |  Issue : 6  |  Page : 860-865

The effect of zolmitriptan on cardiac autonomic modulation in patients with migraine: A double-blind, placebo-controlled, crossover study


1 Department of Cardiology, Faculty of Medicine, Dumlupinar University, Kutahya, Turkey
2 Department of Neurology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, Turkey
3 Department of Internal Medicine, Faculty of Medicine, Dumlup?nar University, Kutahya, Turkey
4 Department of Cardiology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, Turkey

Date of Web Publication20-Nov-2015

Correspondence Address:
Celal Kilit
Department of Cardiology, Faculty of Medicine, Dumlupinar University, Kutahya Evliya Celebi Training and Research Hospital, Evliya Celebi Quarter, Okmeydani Street, 43050, Kutahya
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.170072

Rights and Permissions

 » Abstract 

Background: Triptans, which activate 5-hydroxytryptamine (5-HT)-1B/1D receptors in cerebral arteries, are very effective in aborting attacks of migraine. Although activation of 5-HT-1B/1D receptors diminishes the secretion of noradrenaline from cardiac sympathetic nerves, some studies report that they may cause chest discomfort, myocardial infarction and arrhythmias due to coronary vasospasm. The effect of zolmitriptan on cardiac autonomic modulation has not been evaluated in migraineurs.
Subjects and Methods: Ten patients with migraine (nine women, mean age 33 ± 4 years) were crossover randomized to 2.5 mg zolmitriptan or identical placebo at least 5 days apart. Both time domain parameters (the mean R-R interval, the standard deviation of RR interval [SDNN], and the root mean square of successive R-R interval differences) and frequency domain parameters (low frequency [LF], high frequency [HF], and LF/HF ratio) of heart rate variability (HRV) were obtained during supine position, controlled respiration and handgrip exercise before and 2 h after zolmitriptan or placebo administration.
Results: Baseline HRV parameters were similar for each occasion. Single dose zolmitriptan administration did not affect both time and frequency domain HRV parameters compared with the placebo.
Conclusions: A single dose, 2.5 mg oral zolmitriptan administration did not change sympathetic and parasympathetic reactivity and sympathovagal balance in migraineurs.


Keywords: Cardiac autonomic functions; heart rate variability; migraine; zolmitriptan


How to cite this article:
Kilit C, Oruc S, Kilit TP, Onrat E. The effect of zolmitriptan on cardiac autonomic modulation in patients with migraine: A double-blind, placebo-controlled, crossover study. Neurol India 2015;63:860-5

How to cite this URL:
Kilit C, Oruc S, Kilit TP, Onrat E. The effect of zolmitriptan on cardiac autonomic modulation in patients with migraine: A double-blind, placebo-controlled, crossover study. Neurol India [serial online] 2015 [cited 2019 Dec 8];63:860-5. Available from: http://www.neurologyindia.com/text.asp?2015/63/6/860/170072



 » Introduction Top


Migraine is a complex disease that affects about 15% of the population and can be highly disabling.[1] Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraine and cluster headaches. They were first introduced in the 1990s. While being effective in treating individual headaches, they do not provide preventive treatment and are not considered as curative. Triptans have several advantages over ergotamine and dihydroergotamine in having a selective pharmacology, a well-established safety record, and evidence-based prescribing instructions. Therefore, triptans are often the preferred medications in migraine.[2] Sumatriptan was the first drug in this class and binds to 5-hydroxytryptamine (5-HT)-1B receptors. Zolmitriptan is a new member of triptans and is a serotonin (5-HT) derivative with agonist activity at 5-HT-1B/1D receptors.[2],[3] By activating 5-HT-1B/1D receptors, they lead to vasoconstriction of the cerebral blood vessels, which are dilated during migraine attacks.[4] Moreover, they reduce the secretion of vasoactive peptides and the conduction of painful stimuli in the cerebral cortex.[4] Although triptans exert their therapeutic effect through cerebral vasoconstriction, studies have also documented vasoconstriction in the coronary, pulmonary, and systemic circulation.[5] Triptans are generally better tolerated than ergot alkaloids but chest discomfort can occur as a side effect after administration of triptans. Up to 15% of patients consistently report chest symptoms, including chest pressure, tightness, and discomfort, often mimicking angina pectoris. Fortunately, these are usually transient, mild, and terminate without ischemia. However, a few sporadic ischemic events induced by zolmitriptan have been reported in the literature.[6] It has been shown that triptans constricted the human coronary arteries in vitro. However, apart from avitriptan, therapeutic plasma concentrations of the drugs do not reach levels that are likely to cause myocardial ischemia in individuals with normal coronary circulation.[7],[8],[9],[10],[11] Rarely, triptans may also cause arrhythmias that can be fatal. Even though the cause of the arrhythmias is not known definitely, it has been considered that they may be associated with coronary vasoconstriction.[12],[13],[14] Sumatriptan is, therefore, contraindicated in patients with coronary artery disease.

Heart rate variability (HRV), which can easily be determined non-invasively, has been used to determine risk stratification in cardiological and non-cardiological diseases. Cardiac autonomic dysfunction has been identified with HRV in smokers and in patients with diabetes mellitus or left ventricular dysfunction, as well as in patients after a myocardial infarction.[15],[16],[17],[18],[19] The risk is estimated with the analysis of frequency and time domain parameters of HRV in short-term recordings (5-min). Different conditions such as an upright position, mental stress, and exercise induced sympathetic stimulation consequently change heart rate and HRV parameters.

The aim of this study was to investigate the effects of zolmitriptan on cardiac autonomic function during rest and mild exercise that cause sympathetic activation, and during controlled respiration that causes parasympathetic activation.


 » Subjects and Methods Top


Ten patients (nine female) with migraine, with the mean age being 33 ± 4 years (range: 18–54 years) were included in the study. The single male patient was 35 years old. The average duration of migraine was 5.5 years in the female patients and 6 years in the male patient. Thirty-one percent of female patients had a family history of migraine while the solitary male patient did not. The diagnosis of migraine was established according to the criteria of Headache Classification Committee of the International Headache Society.[20] The participants who had a history of coronary artery disease, or of respiratory, neurological or other systemic disorders that might influence the autonomic function, such as allergy to zolmitriptan, a history of smoking, and the presence of diabetes mellitus, were excluded from the study. Their physical examination, resting 12-lead electrocardiograms, and exercise treadmill tests were in the normal range. Routine laboratory tests including fasting blood glucose, blood urea nitrogen, serum electrolytes, and hemoglobin levels were in the normal range as well. Written informed consent was obtained from all participants, and the Departmental Ethical Committees of Cardiology and Neurology approved the protocol of the study. During the study, we complied with the World Health Organization Declaration of Helsinki and World Psychiatric Association, Good Clinical Practices and Good Laboratory Practice rules.

The participants were involved in a randomized, double-blinded, placebo-controlled, crossover study with two identical experimental sessions conducted at least 5 days apart. They were studied in the morning following at least 8 h of sleep and after having breakfast free of caffeine-containing beverages.

All HRV parameters were recorded in a dimly lighted room with a comfortable temperature (22–24°C). The results were determined by frequency and time domain analysis of HRV in short-term recordings (5-min). As we know, heart rate and HRV parameters change under different conditions such as upright position, mental stress, exercise, and controlled breathing. These conditions cause stimulation of sympathetic or parasympathetic activity. Controlled respiration is used to activate the parasympathetic system, and exercise in an upright position and mental stress are used to activate the sympathetic system. After an adaptation period of at least 15 min rest in supine position, their electrocardiograms were recorded during rest in supine position, controlled respiration (15 breaths/min) in supine position, and during handgrip exercise in sitting position for 5-min intervals. In order to achieve 15 breaths/min, subjects inspired (2-s) and expired (2-s) in synchrony with a metronome. Participants performed an isometric handgrip exercise at 25% of their predetermined maximum voluntary contraction in a manner of 45-s contraction and 15-s resting/min using Jamar hydraulic hand dynamometer (Sammons Preston, Canada). After basal data had been obtained, participants received a single oral dose of 2.5 mg zolmitriptan or placebo with 200 ml water. The order of administration of zolmitriptan or placebo was randomized and participants and operators were blinded to the test. Two hours after taking zolmitriptan or placebo, the participants once again underwent the same procedures as mentioned above. Blood pressure measurements were obtained from the left arm supported at heart level by a trained physician using a sphygmomanometer.

The electrocardiographic data were fed into a personal computer and digitized via an analog-to-digital conversion board (PC-ECG 1200, Norav Medical Ltd., Israel). All recordings were visually examined and manually over-read to verify beat classification. Abnormal beats and artifacts were automatically and manually identified and excluded. HRV analysis was performed by the HRV Software (version 4.2.0, Norav Medical Ltd., Israel). Both time and frequency domain analyses were performed. For the time domain analysis, the mean R-R interval (mean-R-R), the standard deviation of R-R interval (SDNN), and the root mean square of successive R-R interval differences (rMSSD) were measured. For the frequency domain analysis, power spectral analysis based on the fast Fourier transformation algorithm was used. Three components of power spectrum were computed using the following bandwidths: High frequency [HF] (0.15–0.4 Hz), low frequency [LF] (0.04–0.15 Hz), and a detectable part of the very LF spectral band (up to 0.04 Hz). The LF/HF ratio was also calculated.

SPSS computer program (Statistical Package for the Social Sciences version 13.0, SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. Data were presented as mean with a standard error of the mean. Dependent variables at basal levels, and after placebo or zolmitriptan administration were tested with Wilcoxon Signed Rank test and P < 0.05 was considered as statistically significant.


 » Results Top


All participants well-tolerated the study and no adverse effects such as chest discomfort, palpitation, tremor, headache, and rhythm disturbances were observed. Neither time domain nor frequency domain HRV parameters were different during rest, controlled respiration, and handgrip exercise before administering zolmitriptan versus placebo [Table 1].
Table  1: HRV parameters before administering zolmitriptan versus placebo

Click here to view


Zolmitriptan administration did not change systolic (SBP) and diastolic blood pressures (DBP) compared with placebo, during rest [(SBP) 103 ± (DBP) 7/65 ± (standard deviation) 4 mmHg, placebo: 107 ± 5/73 ± 6 mmHg, P > 0.05), controlled respiration (zolmitriptan: 106 ± 5/68 ± 3 mmHg, placebo: 104 ± 4/70 ± 3 mmHg, P > 0.05), and handgrip exercise (zolmitriptan: 123 ± 5/82 ± 3 mmHg, placebo: 125 ± 4/91 ± 3 mmHg, P > 0.05). Furthermore, there were no significant differences in time and frequency domain HRV parameters obtained during rest, controlled respiration, and handgrip exercise after zolmitriptan administration when compared with placebo [Table 2]. Mean R-R interval and LF/HF ratio after zolmitriptan and placebo administrations are shown in [Figure 1] and [Figure 2].
Table  2: HRV parameters after administering zolmitriptan versus placebo

Click here to view
Figure 1: Mean R-R interval after zolmitriptan and placebo administration

Click here to view
Figure 2: Low frequency/high frequency ratio after zolmitriptan and placebo administration

Click here to view



 » Discussion Top


The results of the present study show that time and frequency domain parameters of HRV did not change after 2.5 mg zolmitriptan administration. In a few studies, it has been shown that there was autonomic dysfunction in patients with migraine.[21],[22],[23],[24],[25] However, it is not known definitely, whether the autonomic dysfunction occurs as a consequence of, or is the reason for the precipitation of migraine.[21] Both sympathetic and parasympathetic dysfunctions have been observed in patients with migraine.[23],[24],[25] Furthermore, dysfunctions of the serotonin and monoamine systems located in the brainstem were shown in patients with migraine.[26]

The effects of triptans are primarily on the serotonin system.[27] The effects of serotonin on the cardiovascular system have been found to be variable in various experimental studies and may include bradycardia-tachycardia, vasodilatation-vasoconstriction, and hypotension-hypertension via different receptors. While bradycardia is mediated by stimulation of 5-HT3 receptors in most of the species, tachycardia can be mediated by stimulation of different receptors.[28],[29],[30] Another effect of serotonin on the cardiovascular system is the vasoconstriction of coronary arteries by activation of 5-HT-1B and 5-HT-2A receptors.[31] 5-HT-1B/1D receptors are located in sensory trigeminal fibers of meningeal blood vessels and activation of these receptors by triptans provides pain relief in migraine.[27] 5-HT-1B/1D receptors are also found in different tissues of the cardiovascular system such as human atrium and saphenous vein. The activation of 5-HT-1B/1D receptors in the atrium diminishes the secretion of noradrenaline from noradrenergic axon terminals.[32],[33] It has been shown that sumatriptan also diminishes the secretion of noradrenaline from cardiac sympathetic nerves by activation of 5-HT-1B/1D receptors.[34]

Triptans have been used in aborting attacks of migraine and cluster headache for 24 years. They are more effective than ergot alkaloids in these circumstances and sumatriptan is the most widely used medication.[35] A prevalence of cardiovascular side effects has increased since the drug has started being frequently used. Although it has been reported that sumatriptan caused chest symptoms such as angina pectoris in 15% of patients, recent studies showed that these symptoms were generally not serious and were not explained by ischemia.[9],[11],[12],[13],[14],[36],[37],[38] Serious cardiovascular events such as myocardial infarction have most often been reported in patients with significant cardiovascular risk or in those with an overt cardiovascular disease.[39] Serious cardiac side effects of sumatriptan limited the administration of new generation triptans in migraineurs with coronary artery disease. Lesser cardiovascular side effects, however, have been observed with new generation triptans. As a matter of fact, the side effects of zolmitriptan have been investigated in 2750 patients with migraine, and no ischemic events and electrocardiographic changes have been detected.[40]

In this study, the effects of zolmitriptan on cardiac autonomic functions were assessed according to changes in HRV. Zolmitriptan did not change the time domain parameters (SDNN, RMSSD, and mean R-R) and frequency domain parameters (LF and HF spectral powers and LF/HF ratio) of HRV when compared with placebo. The results of this study are correlated with another study, which investigated the effect of naratriptan on cardiac autonomic functions.[41] We thought that the decrease of noradrenaline secretion by activation of 5-HT-1B/1D receptors on the atrium, as well as on cardiac sympathetic nerves could cause a sympathetic withdrawal of cardiac autonomic activity or a change of sympathovagal balance.[32],[33],[34] However, zolmitriptan administration neither caused sympathetic withdrawal nor changed the sympathovagal balance in our study. A subtle change in parasympathetic activity can affect HRV as mentioned before, but together with the same change in the sympathetic system, may not affect HRV.[16] Therefore, we suggest that small decreases of noradrenaline due to zolmitriptan administration did not affect cardiac autonomic function. However, the possibility remains that the zolmitriptan dose administered in our study might be too low to assess its effect on cardiac autonomic function.

The major limitation of this study was the dose of zolmitriptan administered to the patients. We administered 2.5 mg zolmitriptan to the participants. Some patients with migraine may need more than 2.5 mg zolmitriptan for the alleviation of their symptoms during a migraine attack.

In the present study, we did not observe a significant change in sympathetic or parasympathetic reactivity, and sympathovagal balance after the administration of 2.5 mg zolmitriptan. This observation showed that a single dose, oral administration of 2.5 mg of zolmitriptan did not change cardiac autonomic activity. In light of these findings, zolmitriptan may be preferred in the treatment of migraine especially in individuals having a cardiovascular disease.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
 » References Top

1.
Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007;13:39-44.  Back to cited text no. 1
    
2.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.  Back to cited text no. 2
    
3.
Sturzenegger M, Daems K, Billeter M. Zolmitriptan in treatment of migraine attack – The ARES Study. Schweiz Med Wochenschr 2000;130:1984-93.  Back to cited text no. 3
    
4.
Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87.  Back to cited text no. 4
    
5.
MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87:401-5.  Back to cited text no. 5
    
6.
Kocaoglu I, Gökaslan S, Karagöz A, Sahin D, Ucar Ö, Aydogdu S. Zolmitriptan-induced acute myocardial infarction. Cardiol J 2012;19:76-8.  Back to cited text no. 6
    
7.
Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995;40:245-51.  Back to cited text no. 7
    
8.
Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-98.  Back to cited text no. 8
    
9.
Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998;55:889-922.  Back to cited text no. 9
    
10.
MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.  Back to cited text no. 10
    
11.
Bateman DN. Triptans and migraine. Lancet 2000;355:860-1.  Back to cited text no. 11
    
12.
Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ 2000;321:275.  Back to cited text no. 12
    
13.
Laine K, Raasakka T, Mäntynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511-2.  Back to cited text no. 13
    
14.
Peters RH, Meyburg HW, Westendorp PH, Westerhof PW. Use of sumatriptan (Imigran) in a female patient with coronary spasm. Ned Tijdschr Geneeskd 1994;138:1872-4.  Back to cited text no. 14
    
15.
Alyan O, Kaçmaz F, Ozdemir O, Karahan Z, Taskesen T, Iyem H, et al. High levels of high-sensitivity C-reactive protein and impaired autonomic activity in smokers. Turk Kardiyol Dern Ars 2008;36:368-75.  Back to cited text no. 15
    
16.
Malik M. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354-81.  Back to cited text no. 16
    
17.
Casolo GC, Stroder P, Signorini C, Calzolari F, Zucchini M, Balli E, et al. Heart rate variability during the acute phase of myocardial infarction. Circulation 1992;85:2073-9.  Back to cited text no. 17
    
18.
Casolo G, Balli E, Taddei T, Amuhasi J, Gori C. Decreased spontaneous heart rate variability in congestive heart failure. Am J Cardiol 1989;64:1162-7.  Back to cited text no. 18
    
19.
Pagani M, Malfatto G, Pierini S, Casati R, Masu AM, Poli M, et al. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. J Auton Nerv Syst 1988;23:143-53.  Back to cited text no. 19
    
20.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalagia 1988;8 Suppl 7:1-96.  Back to cited text no. 20
    
21.
Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: A population-based, case-control study. Neurology 2002;58:422-7.  Back to cited text no. 21
    
22.
Yakinci C, Mungen B, Er H, Durmaz Y, Karabiber H. Autonomic nervous system function in childhood migraine. Pediatr Int 1999;41:529-33.  Back to cited text no. 22
    
23.
Araki N. Autonomic nervous activity in migraine. Rinsho Shinkeigaku 1995;35:1336-8.  Back to cited text no. 23
    
24.
Pogacnik T, Sega S, Pecnik B, Kiauta T. Autonomic function testing in patients with migraine. Headache 1993;33:545-50.  Back to cited text no. 24
    
25.
Thomsen LL, Iversen HK, Boesen F, Olesen J. Transcranial Doppler and cardiovascular responses during cardiovascular autonomic tests in migraineurs during and outside attacks. Brain 1995;118:1319-27.  Back to cited text no. 25
    
26.
Sliwka U, Harscher S, Diehl RR, van Schayck R, Niesen WD, Weiller C. Spontaneous oscillations in cerebral blood flow velocity give evidence of different autonomic dysfunctions in various types of headache. Headache 2001;41:157-63.  Back to cited text no. 26
    
27.
Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11.  Back to cited text no. 27
    
28.
Saxena PR. Nature of 5-hydroxytryptamine receptors in mammalian hearts. Prog Pharmacol 1986;6:173-85.  Back to cited text no. 28
    
29.
Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 1990;15 Suppl 7:S17-34.  Back to cited text no. 29
    
30.
Saxena PR, Villalón CM. 5-Hydroxytryptamine: A chameleon in the heart. Trends Pharmacol Sci 1991;12:223-7.  Back to cited text no. 30
    
31.
Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49-56.  Back to cited text no. 31
    
32.
Medhurst AD, Novotny GE, Parker SG, Deighton NM, Kaumann AJ. Effects of 6-hydroxydopamine on pre- and post-junctional 5-HT1-like receptor-mediated responses in dog saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 1993;347:257-65.  Back to cited text no. 32
    
33.
Molderings GJ, Frölich D, Likungu J, Göthert M. Inhibition of noradrenaline release via presynaptic 5-HT1D alpha receptors in human atrium. Naunyn Schmiedebergs Arch Pharmacol 1996;353:272-80.  Back to cited text no. 33
    
34.
Göthert M, Fink K, Frölich D, Likungu J, Molderings G, Schlicker E, et al. Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system. Behav Brain Res 1996;73:89-92.  Back to cited text no. 34
    
35.
McCarthy BG, Peroutka SJ. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache 1989;29:420-2.  Back to cited text no. 35
[PUBMED]    
36.
Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996;36:329-31.  Back to cited text no. 36
    
37.
Hack JB. Oral sumatriptan-induced myocardial infarction. J Toxicol Clin Toxicol 2004;42:309-11.  Back to cited text no. 37
    
38.
Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-25.  Back to cited text no. 38
    
39.
Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: A review of clinical data. Headache 2004;44 Suppl 1:S20-30.  Back to cited text no. 39
    
40.
Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on >3000 subjects treated with zolmitriptan. Cephalalgia 1997;17 Suppl 18:41-52.  Back to cited text no. 40
    
41.
Onrat E, Kaya D, Demirkirkan K. The effect of naratriptan on cardiac autonomic function in patients with migraine: A placebo controlled pilot study. Ceska Slov Neurol Neurochir 2004;4:246-51.  Back to cited text no. 41
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow